Glucagon-like peptide 1 receptor agonist: A potential game changer for cholangiocarcinoma

Table 1 Epidemiological studies on associations of glucagon-like peptide-1 receptor agonist and risk of cholangiocarcinoma

Ref.	Region of study	Study design	Results (95%CI)
Abrahami et al[26], 2018	United Kingdom	Cohort study	HR: 1.97 (0.83-4.66)
Giorda et al[28], 2020	Italy	Case-control study	OR: 1.09 (0.63-1.89)
Ueda et al[27], 2021	Scandinavia	Cohort study	HR: 1.25 (0.89-1.76)
He et al[29], 2022	Worldwide	Systematic review and meta-analysis	RR: 1.43 (0.80-2.56)

HR: Hazard ratio; OR: Odds ratio; RR: Risk ratio.